GSK (LSE:GSK) is drawing fresh attention after a cluster of events, including new oncology and HIV clinical readouts, an expanded Alamar Biosciences collaboration, and a patent settlement with Moderna that reshaped the story around its specialty medicines focus.
At a latest share price of £18.87, GSK has inched higher over 2026, with a 30 day share price return of 6.55% that contrasts with a much gentler 3.03% year to date gain. A 52.42% three year total shareholder return points to momentum that has built over a longer stretch as investors absorb oncology data, the Moderna patent truce and fresh respiratory and HIV updates.
Spot opportunities around GSK's specialty medicines momentum by scanning our hand picked list of solid balance sheet and fundamentals (9 results).After a sharp three year run that has outpaced recent gains, backed by specialty medicines news and fresh guidance, does GSK’s current £18.87 tag still offer an appealing balance between upside potential and downside risk?
Most Popular Narrative: 13% Undervalued
On the Simply Wall St analyst consensus Narrative, GSK’s fair value of £21.73 sits above the latest £18.87 close. This frames the current oncology, HIV and vaccines story as still underappreciated despite the recent share price climb.
The oncology portfolio is scaling through business development backed precision and antibody drug conjugate assets, including the Nuvalent programs and broad Phase III plans for agents such as Mo rez and Ris rez across lung, gynecologic, prostate, GIST and myeloma indications. This can expand future specialty medicines revenue and improve mix driven margins.
See why 232 investors see GSK as 13% undervalued.
Result: Fair Value of £21.73 (UNDERVALUED)
Still, pressure on GSK’s general medicines pricing and any setback in late stage oncology or HIV programs could quickly weaken confidence in that undervaluation story.
Find out about the key risks to this GSK narrative.
Next Steps
That 13% undervaluation view is only one side of the story, and new oncology and HIV news flows quickly. Weigh both the optimism and the concerns for yourself by checking the 3 key rewards and 3 important warning signs.
Looking for more ideas beyond GSK?
Do not stop at a single story. Broaden your watchlist with fresh, high quality ideas sourced from focused screeners that surface different angles on risk and return.
- Target stability first and sort for resilient companies by using the 5 resilient stocks with low risk scores.
- Hunt for mispriced opportunities and scan the 17 high quality undervalued stocks before capital chases them and valuations tighten.
- Build a cash flow focused portfolio and comb through the 4 dividend fortresses while yields and balance sheet strength still line up.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com